<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396315</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR5220</org_study_id>
    <nct_id>NCT03396315</nct_id>
  </id_info>
  <brief_title>Bisphosphonates for Prevention of Post-Denosumab Bone Loss</brief_title>
  <official_title>Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women With Idiopathic Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the study is to assess the extent to which bisphosphonate therapy will
      prevent decreases in bone mass that may occur after cessation of denosumab in premenopausal
      women with idiopathic osteoporosis (IOP) enrolled in AAAN0161 (FD05114) &quot;Denosumab for the
      prevention of post-teriparatide bone loss in premenopausal women with idiopathic
      osteoporosis&quot;.

      In addition, the investigator will observe participants for a second year off bisphosphonate
      therapy to assess duration of response.

      The hypothesis is that bisphosphonate therapy with alendronate or zoledronic acid, initiated
      after recovery of bone remodeling activity, will prevent significant bone loss after
      discontinuing denosumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis in premenopausal women with normal menstrual function and no specific cause is
      termed idiopathic osteoporosis (IOP). IOP is a rare disease with an estimated prevalence of
      &lt;200,000 affected premenopausal women in the United States.

      Women with IOP completing at least one year and up to three years of denosumab (Protocol
      AAAN0161) will be offered participation in this open-label study in which they would choose
      whether to take oral alendronate 70 mg weekly for 12 months or a single intravenous dose of
      zoledronic acid 5 mg. Subjects and study personnel will be blinded to BMD outcomes until 12
      months.

      Discontinuation of denosumab is followed by substantial increases in bone turnover markers to
      well above baseline, bone resorption reaching twice baseline levels for about 6 months. Over
      the first 12 months off therapy, all the bone density gained on treatment is lost. Studies
      done at the institution has demonstrated the occurrence of multiple vertebral fractures in
      some patients who have stopped denosumab. Based upon these new fracture data, the Prolia
      label is currently recommending that consideration should be given to transition to another
      antiresorptive drug in patients stopping denosumab. The main goals of this extension study
      are to determine rates of bone loss and incidence of radiographic vertebral fractures during
      one year of bisphosphonate therapy (oral alendronate or intravenous zoledronic acid)
      initiated after completing denosumab.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open-label study in which they would choose whether to take oral alendronate 70 mg weekly for 12 months or a single intravenous dose of zoledronic acid 5 mg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in BMD at the Lumbar spine (L1-4) within group</measure>
    <time_frame>Baseline, 12 month</time_frame>
    <description>Within-group difference (percent change) in BMD at the lumbar spine (L1-4) will be measured by Dual-energy X-ray absorptiometry (DXA) and calculated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>IOP</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive oral alendronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zoledronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive zoledronic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis</description>
    <arm_group_label>alendronate</arm_group_label>
    <other_name>fosamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis</description>
    <arm_group_label>zoledronic acid</arm_group_label>
    <other_name>Reclast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All women completing at least 12 months of Forteo treatment and at least 12 months of
             denosumab under previous research studies who remain without a diagnosis of an
             excluded medical condition and medication exposures as detailed below, will be offered
             enrollment into this study.

        Exclusion Criteria:

          -  Known intolerance to calcium supplements

          -  Contraindications to bisphosphonate treatment:

               1. Hypocalcemia

               2. Pregnancy

               3. Known hypersensitivity to bisphosphonates

          -  History of osteomalacia

          -  History of osteonecrosis of the jaw

          -  History of dental extraction or other invasive dental surgery within the prior 4 weeks

          -  Invasive dental work planned in the next 12 months

          -  Any condition or illness (acute, chronic, or history), which in the opinion of the
             Investigator might interfere with the evaluation of efficacy and safety during the
             study or may otherwise compromise the safety of the subject

          -  Self-reported or known alcohol or drug abuse within the previous 12 months

          -  Current or recent (within 1 year of enrollment) inflammatory bowel disease or
             malabsorption

          -  Abnormal laboratory tests performed during Visit 1

               1. Renal insufficiency or liver disease: estimated glomerular filtration rate (eGFR)
                  &lt; 35 ml/min, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &gt;50%
                  above upper limit of normal

               2. Hypercalcemia, hypocalcemia

               3. Vitamin D deficiency: 25-Hydroxyvitamin D (25-OHD) &lt; 30 ng/mL

          -  Subjects must be willing to participate voluntarily. Specifically excluded are the
             following: 1) women less than 20 (or 35 in the case of those who wish to participate
             because they have low BMD); 2) protected individuals (institutionalized); 3)
             prisoners; 4) any other prospective participant who, for any reason, might not be able
             to give voluntary informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Shane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariana Bucovsky, BA</last_name>
    <phone>212-305-7225</phone>
    <email>mb3523@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>402-280-4470</phone>
    </contact>
    <investigator>
      <last_name>Robert Recker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joan Lappe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Bucovsky, BA</last_name>
      <phone>212-305-7225</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Shane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adi Cohen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://columbiamedicine.org/divisions/Endo/index.shtml</url>
    <description>Department of Endocrinology at Columbia University</description>
  </link>
  <reference>
    <citation>Cohen A, Recker RR, Lappe J, Dempster DW, Cremers S, McMahon DJ, Stein EM, Fleischer J, Rosen CJ, Rogers H, Staron RB, Lemaster J, Shane E. Premenopausal women with idiopathic low-trauma fractures and/or low bone mineral density. Osteoporos Int. 2012 Jan;23(1):171-82. doi: 10.1007/s00198-011-1560-y. Epub 2011 Mar 2.</citation>
    <PMID>21365462</PMID>
  </reference>
  <reference>
    <citation>Cohen A, Dempster DW, Recker RR, Stein EM, Lappe JM, Zhou H, Wirth AJ, van Lenthe GH, Kohler T, Zwahlen A, Müller R, Rosen CJ, Cremers S, Nickolas TL, McMahon DJ, Rogers H, Staron RB, LeMaster J, Shane E. Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab. 2011 Oct;96(10):3095-105. doi: 10.1210/jc.2011-1387. Epub 2011 Aug 10.</citation>
    <PMID>21832117</PMID>
  </reference>
  <reference>
    <citation>Cohen A, Lang TF, McMahon DJ, Liu XS, Guo XE, Zhang C, Stein EM, Dempster DW, Young P, Saeed I, Lappe JM, Recker RR, Shane E. Central QCT reveals lower volumetric BMD and stiffness in premenopausal women with idiopathic osteoporosis, regardless of fracture history. J Clin Endocrinol Metab. 2012 Nov;97(11):4244-52. doi: 10.1210/jc.2012-2099. Epub 2012 Sep 7.</citation>
    <PMID>22962425</PMID>
  </reference>
  <reference>
    <citation>Cohen A, Liu XS, Stein EM, McMahon DJ, Rogers HF, Lemaster J, Recker RR, Lappe JM, Guo XE, Shane E. Bone microarchitecture and stiffness in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab. 2009 Nov;94(11):4351-60. doi: 10.1210/jc.2009-0996. Epub 2009 Oct 16.</citation>
    <PMID>19837923</PMID>
  </reference>
  <reference>
    <citation>Cohen A, Stein EM, Recker RR, Lappe JM, Dempster DW, Zhou H, Cremers S, McMahon DJ, Nickolas TL, Müller R, Zwahlen A, Young P, Stubby J, Shane E. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab. 2013 May;98(5):1971-81. doi: 10.1210/jc.2013-1172. Epub 2013 Mar 29.</citation>
    <PMID>23543660</PMID>
  </reference>
  <reference>
    <citation>Nishiyama K, Wang J, Young P, et al. Teriparatide Is Associated with Improved Microarchitecture and Estimated Bone Strength in Premenopausal Women with Idiopathic Osteoporosis: An HR-pQCT Study. American Society for Bone and Mineral Research Annual Meeting; 2013; Baltimore, MD: American Society for Bone and Mineral Research</citation>
  </reference>
  <reference>
    <citation>Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001 May;16(5):925-31.</citation>
    <PMID>11341338</PMID>
  </reference>
  <reference>
    <citation>Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998 Oct 15;102(8):1627-33.</citation>
    <PMID>9788977</PMID>
  </reference>
  <reference>
    <citation>Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. 2000 May;15(5):944-51.</citation>
    <PMID>10804025</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, Arnold AL. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab. 1999 Apr;84(4):1214-9.</citation>
    <PMID>10199756</PMID>
  </reference>
  <reference>
    <citation>Cohen A, Kamanda-Kosseh M, Recker RR, Lappe JM, Dempster DW, Zhou H, Cremers S, Bucovsky M, Stubby J, Shane E. Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis. J Clin Endocrinol Metab. 2015 Nov;100(11):4208-14. doi: 10.1210/jc.2015-2829. Epub 2015 Sep 10.</citation>
    <PMID>26358172</PMID>
  </reference>
  <reference>
    <citation>Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2.</citation>
    <PMID>21289258</PMID>
  </reference>
  <reference>
    <citation>Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008 Aug;43(2):222-9. doi: 10.1016/j.bone.2008.04.007. Epub 2008 Apr 26.</citation>
    <PMID>18539106</PMID>
  </reference>
  <reference>
    <citation>Anastasilakis AD, Makras P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int. 2016 May;27(5):1929-30. doi: 10.1007/s00198-015-3459-5. Epub 2015 Dec 22.</citation>
    <PMID>26694593</PMID>
  </reference>
  <reference>
    <citation>Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. J Bone Miner Res. 2017 Jun;32(6):1291-1296. doi: 10.1002/jbmr.3110. Epub 2017 Mar 13. Review.</citation>
    <PMID>28240371</PMID>
  </reference>
  <reference>
    <citation>Anastasilakis AD, Yavropoulou MP, Makras P. Bisphosphonates or denosumab discontinuation and risk of fractures. Maturitas. 2017 Aug;102:75. doi: 10.1016/j.maturitas.2017.04.016. Epub 2017 Apr 27.</citation>
    <PMID>28495014</PMID>
  </reference>
  <reference>
    <citation>Anastasilakis AD, Yavropoulou MP, Makras P, Sakellariou GT, Papadopoulou F, Gerou S, Papapoulos SE. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol. 2017 Jun;176(6):677-683. doi: 10.1530/EJE-16-1027. Epub 2017 Mar 10.</citation>
    <PMID>28283537</PMID>
  </reference>
  <reference>
    <citation>Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int. 2016 May;27(5):1923-5. doi: 10.1007/s00198-015-3380-y. Epub 2015 Oct 28.</citation>
    <PMID>26510845</PMID>
  </reference>
  <reference>
    <citation>Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report. J Clin Endocrinol Metab. 2017 Feb 1;102(2):354-358. doi: 10.1210/jc.2016-3170.</citation>
    <PMID>27732330</PMID>
  </reference>
  <reference>
    <citation>Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int. 2016 May;27(5):1917-21. doi: 10.1007/s00198-015-3458-6. Epub 2015 Dec 22.</citation>
    <PMID>26694598</PMID>
  </reference>
  <reference>
    <citation>Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL; DAPS Investigators. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012 Jan;23(1):317-26. doi: 10.1007/s00198-011-1780-1. Epub 2011 Sep 17.</citation>
    <PMID>21927922</PMID>
  </reference>
  <reference>
    <citation>Reid IR, Horne AM, Mihov B, Gamble GD. Bone Loss After Denosumab: Only Partial Protection with Zoledronate. Calcif Tissue Int. 2017 Oct;101(4):371-374. doi: 10.1007/s00223-017-0288-x. Epub 2017 May 13.</citation>
    <PMID>28500448</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Elizabeth Shane</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>premenopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

